NEOGENOMICS INC

NeoGenomics, Inc. provides oncology diagnostic testing, technical laboratory services, and professional test interpretations by specialized physicians and molecular experts. The company operates under a single reportable segment encompassing services such as molecular and next-generation sequencing testing, cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, morphologic analysis, and molecular residual disease testing. Additionally, it offers clinical trial and research support services, validation laboratory services, and oncology data solutions. Its customer base includes community-based oncology and pathology practices, hospital laboratories, reference laboratories, academic centers, and pharmaceutical companies.

The company operates a network of testing laboratories across the United States—specifically in Arizona, California, Florida, Georgia, Illinois, New Jersey, North Carolina, Tennessee, and Texas—as well as a sample-processing laboratory in Cambridge, United Kingdom. As of late 2025, the organization employed approximately 2,500 full-time equivalent personnel, including contracted pathologists and around 135 physicians and doctoral specialists. The provided text does not state the company's headquarters location.

Summary of the business section of Neogenomics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 2,500 full-time equivalent employees including contracted pathologists.”